Trial Profile
A Multi-National, Blinded, Placebo-Controlled, Dose Escalation Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of HQK-1001 in Subjects With Beta Thalassemia Intermedia, Including Hemoglobin E Beta Thalassemia
Status:
Completed
Phase of Trial:
Phase I/II
Latest Information Update: 21 Mar 2014
Price :
$35
*
At a glance
- Drugs HQK 1001 (Primary)
- Indications Beta-thalassaemia
- Focus Adverse reactions
- Sponsors HemaQuest Pharmaceuticals
- 21 Mar 2014 New trial record